Thermo Fisher Scientific (TMO) Wolfe Research Healthcare Conference 2024 summary

Industry and market conditions

• Market conditions improved steadily throughout the year, with predictable end markets and consistent business performance.

• Share gain momentum continued, with raised EPS and revenue outlooks despite industry volatility.

• The sector experienced significant value loss during earnings season, with share prices dropping amid external noise.

• Volatility was largely self-imposed by differing company outlooks and expectations.

• Organic growth returned in Q4, with guidance implying about 2.5% growth and solid momentum into 2025.

Impact of political and regulatory changes

• The recent election and potential new HHS leadership led to a 10% share price drop, driven by sector-wide uncertainty.

• A more business-friendly administration is expected, with likely favorable FTC M&A, tax, and jobs environments.

• NIH funding is seen as stable, with bipartisan support and only low single-digit revenue exposure.

• Tariff risks are mitigated by a flexible supply chain and the ability to pass through inflationary pressures.

• China exposure is about 8% of revenue, half the industry average, with modest impact expected from tariffs.

Capital deployment and M&A strategy

• The company maintains an active M&A pipeline, focusing on clear, approvable deals and disciplined returns.

• Volatility may create more M&A opportunities as valuations reset and sellers become more willing.

• A $4 billion share buyback was authorized, with capital deployment split roughly one-third to buybacks/dividends and two-thirds to M&A.

• Over $6 billion in capital was deployed in 2024, including $3 billion in buybacks and $3 billion in M&A.